Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

KRAS-Mutation Colon, Rectal Cancers Have Distinct Survival Profiles

Key clinical point: Clinical trials, personalized medicine may need to be adjusted for primary tumor location.

Major finding: There was no difference in survival for KRAS mutant versus wild type in liver metastases with rectal origin.

Study details: A retrospective analysis (n = 1,304).

Disclosures: The funding source was not disclosed. The authors had no relevant financial disclosures.

Citation:

Amini N et al. J Am Coll Surg. 2019 Oct;229(4):Suppl 1, S69-70.